Lost Money on Supernus Pharmaceuticals, Inc.(SUPN)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky
Portfolio Pulse from
Levi & Korsinsky has initiated an investigation into Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) for potential violations of federal securities laws. This follows the company's announcement that its Phase 2b study of SPN-820 for treatment-resistant depression did not meet its primary endpoint.
March 04, 2025 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Supernus Pharmaceuticals is under investigation by Levi & Korsinsky for potential securities law violations after its SPN-820 study failed to meet primary endpoints.
The failure of the SPN-820 study is a significant setback for Supernus Pharmaceuticals, likely affecting investor confidence and stock price negatively. The legal investigation adds further pressure, suggesting potential legal and financial repercussions.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100